AstraZeneca Pushes DC Circ. To Stretch Seroquel Exclusivity
AstraZeneca PLC told a D.C. Circuit panel Thursday that the U.S. Food and Drug Administration inappropriately refused to extend its exclusivity rights for the antipsychotic Seroquel despite new safety warnings and...To view the full article, register now.
Already a subscriber? Click here to view full article